CEO Ming Hsieh Continues Milestone‑Driven Sales at Fulgent Genetics, Reinforcing Long‑Term Commitment Despite Market Volatility

Insider Activity Highlights the CEO’s Confidence in Fulgent’s Growth Plan

On February 23, 2026, Chief Executive Officer Ming Hsieh sold 2,167 shares of Fulgent Genetics common stock at the prevailing price of $23.09—a move that appears routine when compared to the pattern of his recent transactions. The sale was part of a broader series of restricted‑stock unit (RSU) vestings that unfolded over the past year, with Hsieh exercising and selling a total of nearly 90,000 shares on February 24, 2026. The cumulative effect of these transactions has reduced his direct ownership stake to roughly 0.12 % of the company, while the trust and family holdings still hold a substantial 7.9 million shares, underscoring his long‑term alignment with shareholders.

What This Means for Investors

The volume of shares sold is modest relative to the company’s 7.9 million‑share trust holding and is consistent with a vesting schedule that rewards executive performance. The fact that the sales were executed at the same market price as the sale on February 23—without a price drop—suggests that Hsieh is not attempting to capitalize on a short‑term price spike. Instead, the trades align with the company’s compensation philosophy, which ties executive equity to milestones such as the successful acquisition of Bako Diagnostics and the rollout of StrataDx’s diagnostic platform. For investors, the stability of the CEO’s holdings and the absence of a large, liquid sell‑off mitigate concerns that the top executive is divesting in anticipation of a downturn.

Insider Trading in Context

When viewed alongside the broader insider activity, Hsieh’s pattern stands out for its disciplined vesting approach. Other senior executives—President & COO Xie Jian, CFO Kim Paul, and Chief Scientific Officer Gao Hanlin—have also been active in February, each completing multiple buy‑sell cycles tied to RSU vestings and stock options. The collective activity across the leadership team indicates a coordinated effort to align equity interests with company performance rather than opportunistic trading. The 52‑week high of $31.04 reached last November has yet to be recaptured, and the stock’s negative price‑earnings ratio highlights ongoing losses, but the steady insider buying suggests confidence in the company’s long‑term strategy.

A Profile of Ming Hsieh’s Trading Behavior

Ming Hsieh’s insider history demonstrates a pattern of conservative, milestone‑driven equity transactions. Since mid‑2025, he has sold a consistent block of shares—typically between 1,300 and 3,000 shares—when RSUs vest, and has purchased shares in the 10,000–40,000 range after a vesting event, often at no price (indicating a tax‑withholding mechanism). His largest sell was 2,944 shares on November 26, 2025, and his most recent large sale was the 2,167‑share transaction on February 23, 2026. Hsieh’s overall net exposure has remained small, with no significant accumulation or divestiture beyond the vesting schedule, reflecting a focus on long‑term value creation rather than short‑term speculation.

Conclusion

For investors monitoring Fulgent Genetics, the current insider activity signals a CEO who is closely tracking company milestones while maintaining a modest but significant equity stake through trusts and family holdings. The lack of aggressive selling and the consistent pattern of vesting‑linked transactions suggest confidence in the company’s strategic initiatives—particularly its recent acquisitions and product launches—despite the broader market volatility. As the stock continues to trade below its 52‑week high, a steady insider buying trend may provide a stabilizing anchor for shareholders looking for a long‑term investment in the genetic diagnostics space.